Pathogenic factors associated with development of disseminated intravascular coagulopathy (DIC) in a tertiary academic hospital in South Africa

Elizabeth S. Mayne¹²*, Anthony L. H. Mayne¹, Susan J. Louw¹²

¹ Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ² National Health Laboratory Service, Johannesburg, South Africa

* elizabeth.mayne@nhls.ac.za

Abstract

Introduction
Disseminated intravascular coagulopathy (DIC) is a thrombotic microangiopathy arising from consumption of both coagulation factors and platelets. DIC is triggered by a number of clinical conditions including severe infection, trauma and obstetric complications. Early diagnosis and treatment of the underlying condition is paramount. A high clinical index of suspicion is needed to ensure that patients at risk of developing DIC are appropriately investigated.

Methods
In order to establish the clinical conditions most frequently associated with DIC, we reviewed all DIC screens received at a tertiary hospital in Johannesburg, South Africa over a 1 year period.

Results
The commonest clinical condition associated with DIC in our population was infection with 84% of patients infected with an identified pathogen. The most frequently diagnosed pathogen was HIV followed by Mycobacterium tuberculosis and other bacterial infections. In the majority of cases, bacteria were isolated from blood cultures. In 47 patients, HIV was the only pathogen which could be isolated. A relative risk ratio of 2.73 and an odds ratio of 29.97 was attributed to HIV for development of a DIC. A malignancy was present in 51 of the patients of which approximately 60% had co-existing infection. No cause could be attributed in 30 patients.

Conclusion
Infection was identified in the majority of the patients diagnosed with DIC in this study. HIV showed the highest relative risk ratio of all pathogens although previous studies have not
suggested that HIV was strongly associated with DIC. In almost half of the HIV infected patients, there was no other pathogen isolated despite extensive investigation. This suggests that HIV has a strong association with the development of DIC, warranting further research into the relationship between HIV and disseminated microvascular thrombosis.

Introduction

Disseminated intravascular coagulopathy (DIC) is a syndrome of dysregulation of the haemostatic pathways associated with formation of small vessel microthrombi and consumption of platelets and coagulation factors. [1,2] DIC has been associated with a number of clinical conditions including severe infectious disease and sepsis, [3] malignancy,[4] trauma [5] and obstetric complications [6]. The treatment of DIC consists predominantly of managing the underlying disease process and providing supportive treatment for the coagulopathy.[2, 7, 8] Diagnosis of DIC is made using both clinical and laboratory criteria and a number of scoring systems is available. Parameters measured assess the consumption of coagulation factors (prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen levels), anticoagulant activity (antithrombin) and platelet numbers.

Fibrin degradation products (D-dimers) are also included which demonstrate ongoing fibrinolysis (in the context of widespread clot formation and breakdown). [8] Critically, a diagnosis of DIC should be made in the context of an appropriate clinical trigger. [2,8]

The mainstay of treatment of DIC is resolution of the clinical trigger. In patients who are bleeding or who require invasive procedures (like surgery), replacement of depleted coagulation factors and platelets may be indicated. This replacement therapy is monitored using the PTT and aPTT and the platelet count. [2]

The mechanism underlying the development of DIC is not fully understood. Inflammatory stimuli result in endothelial activation with a change from an anticoagulant to a procoagulant surface. [3, 9] This potentiates the formation of small thrombi which eventually consume coagulation factors and platelets resulting in a bleeding diathesis. Early compensatory mechanisms may delay recognition of this process and it is important for clinicians to have a high index of suspicion in the correct clinical context.[4, 9]

Currently, there are little data regarding the aetiology of DIC in South Africa. This is of concern in a setting with a high prevalence of infectious diseases including human immunodeficiency virus (HIV). Early and accurate identification of potential high risk conditions would assist in risk stratification and may assist in creating algorithmic approaches for these patients. [10] In particular, the impact of HIV and Mycobacterial tuberculosis infection on the risk of developing DIC is poorly understood.

In order to assess the risk factors for development of these conditions, we conducted a retrospective survey of all DIC screens submitted for analysis to the coagulation laboratory at Charlotte Maxeke Johannesburg Academic Hospital, an academic hospital in Johannesburg South Africa over a 1 year period.

Methodology

This study received ethics clearance from the Human Resource Ethics Committee of the University of the Witwatersrand (Clearance number: M160839). Participants were assigned a study number and all data were anonymised. All sequential DIC screens received at the laboratory over the period between May 2015 and April 2016 were included in the analysis (n = 401).
All coagulation testing was conducted on a STAGO EVO-R analyser (Cedex, France) on citrate plasma and the platelet count was assessed using a Siemens Advia 120 Haematology analyser (Erlangen, Germany). Where time-to-clot assays were prolonged, a manual correction using normal factor pool was performed. The following data parameters are assessed routinely on DIC panels: Activated Partial Thromboplastin Time (aPTT) in seconds, Prothrombin Time (PT) in seconds, D-dimer levels in g/dl, Antithrombin levels as a percent, Thrombin Time (TT) in seconds and platelet count. Although not allocated points in the ISTH scoring system, antithrombin levels have been utilised by other scoring systems (like the JSTH scoring system) [11] to indicate consumption of anticoagulant factors. Thrombin time has been used historically in our centre to exclude the presence of heparin contamination. D-dimer cut-off levels for moderate and strong increases were set at 0.25-1mg/L and greater than 1mg/L respectively in accordance with previously calculated interquartile ranges. [2]

Information on all screens was accessed from the laboratory information system. All screens were assessed for completeness of data and were assigned a score based on the ISTH DIC scoring system (Table 1). A score of 5 or greater was considered positive for the presence of a DIC. Screens lacking results for D-dimer levels, fibrinogen, PT or platelet count, were excluded from the analysis. Additional clinical data were retrieved from the laboratory information system including the results of bacteriological cultures, histological analysis, viral testing and biochemical testing.

Statistical analysis was conducted using the STATA statistical package (version 14.2 Stata-corp, Texas, USA). Relative risk and odds ratios were calculated for all possible DIC triggers utilising the following formulae: Relative risk

$$\text{Relative risk} = \frac{\text{DIC positive given disease}}{\text{DIC positive given disease positive and negative}} \times \frac{\text{DIC negative given disease}}{\text{DIC negative given disease positive and negative}}$$

and Odds Ratio:

$$\text{Odds Ratio} = \frac{\text{DIC positive given disease}}{\text{DIC positive given no disease}} \times \frac{\text{DIC negative given disease}}{\text{DIC negative given no disease}}$$

Results

Over the study period, 198 of the 401 patients fulfilled the ISTH diagnostic criteria for a diagnosis of DIC. The median age of the patients at the time of presentation with a DIC was 37 years (range 1 month -76 years) with a female to male ratio of 1.2:1. In the majority of patients (84.3%), infection was present at the diagnosis of DIC. The most prevalent pathogen was HIV

Table 1. ISTH DIC scoring system [10].

| Laboratory Parameter         | Point allocation |
|------------------------------|------------------|
| **Platelet Count**           |                  |
| > 100 x10^9/l                | 0                |
| 50-100x10^9/l                | 1                |
| <50x10^9/l                   | 2                |
| **Increase in Fibrin Markers**|                  |
| No change                    | 0                |
| Moderate rise (> 0.25-1mg/L) | 2                |
| Strong rise (> 1mg/L)        | 3                |
| **Prothrombin Time Prolongation** |            |
| 3 seconds or less            | 0                |
| > 3 seconds but < 6 seconds  | 1                |
| Greater than 6 seconds       | 2                |
| **Fibrinogen Level**         |                  |
| Greater than 1 g/l           | 0                |
| Less than 1 g/l              | 1                |

https://doi.org/10.1371/journal.pone.0195793.t001
which was present in 56.6% of these patients. Bacterial infection (excluding mycobacterial infections) was diagnosed in 49 patients and 20 of these had underlying HIV infection. Mycobacterial infection was present in 28 patients, all of whom were HIV co-infected. Malignancy was present in 25.8% of the patients of whom 60% (30) also had co-existing infection.

The most prevalent bacterial infection in the patients was Mycobacterium tuberculosis which was diagnosed in 28 patients followed by *Klebsiella pneumoniae* which was cultured in 12 patients. (Table 2).

Fungal infections were demonstrated in 12 patients and a further 4 patients had evidence of a suspected fungal infection (an elevated beta-D glucan level) although blood and urine cultures failed to demonstrate a fungal pathogen (Table 3). Only 4 patients had evidence of fungal septicaemia.

Malignancies were present in 51 patients at the time of diagnosis. Haematological malignancies were the most commonly identified (n = 37) with Acute myeloid leukaemia predominating. The commonest solid organ malignancy identified was squamous carcinoma of the cervix which was present in 5 patients at diagnosis (Table 4).

HIV infection, itself, had the highest relative risk ratio for all possible triggers of 2.738 (95% confidence limits 2.32–2.32) followed by bacterial infection. The Odds ratio for development of DIC was highest for mycobacterial infection (Odds ratio of 35.005, 95% confidence limits of 4.7–259.66) followed by HIV and then non-mycobacterial bacterial infections (Table 5).

**Discussion**

Over the study period, 198 patients fulfilled the ISTH DIC criteria for diagnosis of a DIC. As anticipated, the commonest potential trigger for the DIC identified in these patients was infection with a positive assay for viral, mycobacterial, fungal or bacterial infection in approximately 84% of the patients.

The commonest pathogen identified was HIV. HIV has been reported as a potential cause of DIC although this has generally been in association with an opportunistic or co-existing infection or malignancy. [12, 13] HIV infection has been reported more commonly as a trigger for other microangiopathic haemopathies specifically thrombotic thrombocytopenic purpura (TTP). [14, 15] Early studies suggest that DIC is an uncommon complication in HIV. HIV is, however, associated with an increased risk of endothelial dysfunction and activation. [16] The increased risk of dysfunctional clotting in HIV-infected individuals has been attributed to a number of risk factors including low levels of the anticoagulant factor protein S [17], activating antibodies, reduced processing of procoagulant factors like von Willebrand factor and low level chronic inflammation. [18–20] Although a large number of HIV-infected patients (43.8%) in this study were co-infected with an additional pathogen and 16 had an underlying malignancy (14%), in 47 patients (42% of all HIV infected patients), no additional pathology could be found despite extensive investigation and repeated cultures.

The ISTH DIC diagnostic score allocates points for thrombocytopenia, elevated fibrin degradation products (D-dimers), prolonged PT and fibrinogen. Elevated D-dimer levels have been reported in HIV patients, particularly in the context of uncontrolled viraemia. [21] The platelet count is often decreased in these patients for a number of reasons including autoimmune platelet destruction, marrow infiltration and HIV-associated dysphaemopoiesis. [22] Chronic infection with liver synthetic dysfunction in these patients could also result in perturbation of the coagulation cascade and decreased fibrinogen. [23] These factors may impact the laboratory analyses and the diagnosis of DIC in these patients may not reflect a pure consumptive coagulopathy. The clinical presentation is, however, indistinguishable with high morbidity and mortality and the treatment for these patients includes treatment of the underlying cause.
This would include treatment of all infections with initiation of chemotherapy for tuberculosis and antiretroviral therapy where appropriate.

In 30 patients, no clear trigger for the underlying DIC could be ascertained. It is suspected that, in some of these patients, investigation was limited owing to early mortality. HIV testing can only be performed after counselling and consent and it was beyond the scope of the study to test the patients retrospectively. The clinical features were, in some cases, suggestive of underlying immunosuppression.

This study has a number of limitations. Results were assessed retrospectively and no additional testing was performed. Subjects could only be identified if a sample was submitted for DIC screening and it is possible that not all patients in the hospital were appropriately investigated for DIC. This could result in bias as there is an overrepresentation of DIC screens from intensive care units and internal medicine wards where the clinical suspicion for DIC is high. There was an underrepresentation of screens from the surgical, trauma and obstetric

| Organism identified             | Number of patients and site of positive test | HIV status of patient at time of culture | Total |
|---------------------------------|---------------------------------------------|----------------------------------------|-------|
| Mycobacterium tuberculosis      | Blood (n = 8), Sputum GeneXpert (n = 18) Sputum culture (n = 1), Trephine (n = 1) | 0 28 0 | 28   |
| K. pneumoniae                   | Blood (n = 7), Urine (n = 5)                | 6 3 3 | 12   |
| Enterococcus faecalis           | Blood (n = 5), Cerebrospinal fluid (n = 1)  | 3 2 1 | 6    |
| A. baumannii                    | Blood (n = 4), sputum (n = 1)              | 4 1 0 | 5    |
| Coagulase negative staphylococcus | Blood (n = 4), sputum (n = 1)            | 0 4 0 | 4    |
| E. coli                         | Blood (n = 1), urine (n = 4)              | 1 0 0 | 1    |
| S. aureus                       | Blood (n = 4)                             | 0 4 1 | 5    |
| P. aeruginosa                   | Blood (n = 1), Cerebrospinal fluid (n = 1) | 3 1 1 | 5    |
| Streptococcus pyogenes          | Blood (n = 3)                             | 0 2 1 | 3    |
| Salmonella spp.                 | Blood (n = 4)                             | 0 3 1 | 4    |
| Streptococcus pneumoniae        | Blood (n = 4), Cerebrospinal fluid (n = 1) | 0 2 0 | 3    |
| N. meningitidis                 | Blood (n = 2)                             | 0 2 0 | 2    |
| Providentia spp.                | Blood (n = 4)                             | 0 0 2 | 2    |
| H. parainfluenza                | Sputum (n = 1)                            | 0 1 0 | 1    |
| Streptococcus anginosus         | Blood (n = 1)                             | 0 1 0 | 1    |
| Proteus mirabilis               | Urine (n = 1)                             | 0 1 0 | 1    |
| Mixed Growth                    | Urine (n = 3), Blood (n = 1)              | 1 2 1 | 4    |

This table shows the bacteria and mycobacteria identified at the time of DIC diagnosis with the site of culture and HIV status.

| Fungal pathogen    | Site of identification and number of patients | HIV status Negative | Positive | Untested | Total |
|--------------------|-----------------------------------------------|---------------------|----------|----------|-------|
| Candida spp        | Urine (3), Sputum (1), Cervical (2) Blood (1) | 1                   | 5        | 1        | 7     |
| Candida albicans   | Blood (1), Urine (1)                          | -                   | 1        | 1        | 2     |
| Candida parapsilosis| Blood (1)                                     | 1                   | -        | -        | 1     |
| Cryptococcus neoformans | Blood (1), Cerebrospinal fluid (1)    | -                   | 2        | -        | 2     |
| High B-D glucan    | -                                             | 4                   | -        | -        | 4     |

This table shows the fungal pathogens identified at the time of DIC diagnosis.
## Table 4. Underlying malignancies present in patients with diagnostic features of a DIC.

| Primary diagnosis                                      | Staging (Solid organ malignancies) | World Health organisation subtyping (Haematological malignancies) | HIV status | Total |
|---------------------------------------------------------|------------------------------------|--------------------------------------------------------------------|------------|-------|
|                                                         |                                    |                                                                    | Number of patients |      |
|                                                         |                                    |                                                                    | Negative | Positive | Unknown |
| Haematological Malignancies                             |                                    |                                                                    |            |         |         |
| Myelodysplastic syndrome                                |                                    | Myelodysplastic syndrome with excess blasts                        | 2          | 2      |         |
| Acute myeloid leukaemia (AML)                           |                                    | AML with recurrent translocation t(15;17) n = 5                    | 4          | 7      | 4       | 15     |
|                                                         |                                    | AML with recurrent translocation t(8;21) n = 3                    |            |         |         |
|                                                         |                                    | AML NOS, Acute monoclastic n = 1                                  |            |         |         |
|                                                         |                                    | AML not otherwise specified n = 6                                 |            |         |         |
| Chronic Myeloid leukaemia                               |                                    | CML with BCR-ABL1                                                  | -          | -      | 2       | 2      |
| B-cell Acute Lymphoblastic leukaemia (ALL)              |                                    | Not subtyped                                                      | 2          | -      | 1       | 3      |
| Acute leukaemia                                         |                                    |                                                                    |            | 2      |         |         |
| Diffuse Large                                           |                                    | Gastric (n = 1), Plasmablastic (n = 1), NOS (n = 1)                | -          | 2      | 1       | 3      |
| B-cell lymphoma                                         |                                    |                                                                    |            |         |         |         |
| B-cell Lymphoproliferative disorder                     |                                    |                                                                    |            |         |         |         |
| Hairy cell leukaemia                                    |                                    |                                                                    |            |         |         |         |
| Castleman’s Disease                                     |                                    |                                                                    |            |         |         |         |
| Monoclonal gammopathy of uncertain significance         |                                    |                                                                    |            |         |         |         |
| Hodgkin Lymphoma                                        |                                    | Classical (n = 1), Nodular sclerosing HL (n = 1)                   | -          | 3      | -       | 3      |
| Plasma cell myeloma                                     |                                    |                                                                    |            | 1      |         | 2      |
| Solid Organ Malignancies                                |                                    |                                                                    |            |         |         |         |
| Adenocarcinoma                                          |                                    |                                                                    |            |         |         |         |
| Breast Ductal                                           | Stage 4                            |                                                                    | -          | -      | 1       | 1      |
| Ovarian                                                 | Stage 4                            |                                                                    | -          | 1      | 1       | 2      |
| Prostatic                                               | Stage 4                            |                                                                    | 1          | -      | 1       | 2      |
| Squamous carcinoma                                      |                                    |                                                                    |            |         |         |         |
| Cervical                                                | Stage 1 (1)                         |                                                                    | 1          | 3      | 1       | 5      |
|                                                         | Stage 2b (1)                       |                                                                    |            |         |         |         |
|                                                         | Stage 4 (3)                        |                                                                    |            |         |         |         |
| Oesophagus                                              | Stage 4                            |                                                                    | -          | 1      | -       | 1      |
| No identifiable primary                                 | Stage 4                            |                                                                    | -          | -      | 2       | 2      |
| Sarcoma                                                 |                                    |                                                                    |            |         |         |         |
| Kaposi Sarcoma                                          | Stage 4                            |                                                                    | -          | 1      | -       | 1      |

https://doi.org/10.1371/journal.pone.0195793.t004

## Table 5. Relative risk ratios for suspected triggers for DIC.

|                          | Bacterial (non-mycobacterial) | Mycobacterium tuberculosis | Malignancy | HIV      |
|--------------------------|------------------------------|---------------------------|------------|----------|
| Odds ratio               | 27.2199                      | 35.0059                   | 22.7478    | 29.9776  |
| 95% lower confidence limit | 8.3579                      | 4.7193                    | 6.9607     | 12.7020  |
| 95% upper confidence limit | 88.6490                      | 259.6629                  | 74.3400    | 70.7492  |
| Relative risk ratio      | 2.3110                      | 2.1335                    | 2.2310     | 2.7387   |
| 95% lower confidence limit | 2.0104                      | 1.8738                    | 1.9414     | 2.3257   |
| 95% upper confidence limit | 2.6565                      | 2.4292                    | 2.5638     | 3.3257   |

https://doi.org/10.1371/journal.pone.0195793.t005
departments where DIC may be consequently under-diagnosed. It was not possible to determine whether patients fulfilled the criteria for diagnosis of sepsis as commonly used scoring systems require clinical data. [24] The study contained a small number of participants. Finally, it was not possible to follow patients up and the final clinical outcome of the DIC could not be evaluated. The study does, however, highlight the common triggers for DIC in our setting and may alert clinicians to ensure appropriate investigation and treatment.

Author Contributions

Conceptualization: Elizabeth S. Mayne, Susan J. Louw.

Formal analysis: Anthony L. H. Mayne.

Investigation: Elizabeth S. Mayne, Susan J. Louw.

Methodology: Elizabeth S. Mayne, Susan J. Louw.

Writing – original draft: Elizabeth S. Mayne, Susan J. Louw.

Writing – review & editing: Elizabeth S. Mayne, Susan J. Louw.

References

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8):586–92. https://doi.org/10.1056/NEJM199908193410807 PMID: 10451465

2. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009; 145 (1):24–33. PMID: 19222477

3. Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microorganism [ISRCTN74215569]. Crit Care. 2004; 8(2):R82–90. https://doi.org/10.1186/cc2459 PMID: 15025782

4. Toh CH, Alhamdi Y. Current consideration and management of disseminated intravascular coagulation. Hematology Am Soc Hematol Educ Program. 2013; 2013:286–91. https://doi.org/10.1182/asheducation-2013.1.286 PMID: 24319193

5. Gando S, Nanzaki S, Kemmotsu O. Disseminated intravascular coagulation and sustained systemic inflammatory response syndrome predict organ dysfunctions after trauma: application of clinical decision analysis. Ann Surg. 1999; 229(1):121–7. PMID: 9923809

6. Davies S. Amniotic fluid embolism and isolated disseminated intravascular coagulation. Can J Anaesth. 1999; 46(5 Pt 1):456–9. https://doi.org/10.1007/BF03012944 PMID: 10349924

7. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. 2014; 2(1):15. https://doi.org/10.1186/2052-0492-2-15 PMID: 25520831

8. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, Gando S, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013.

9. Bick RL, Arun B, Frenkel EP. Disseminated intravascular coagulation, clinical and pathophysiological mechanisms and manifestations. Haemostasis. 1999; 29(2–3):111–34. https://doi.org/10.1159/000022493 PMID: 10629392

10. Taylor FB Jr., Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on T, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001; 86 (5):1327–30. PMID: 11816725

11. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, et al. A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. Clin Appl Thromb Hemost. 2017:1076029617720069.

12. Fera G, Semeraro N, De Mitrio V, Schiraldi O. Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome. Infection. 1993; 21(3):171–3. PMID: 8365814
13. Bilgrami S, Cable R, Pisciotto P, Rowland F, Greenberg B. Fatal disseminated intravascular coagulation and pulmonary thrombosis following blood transfusion in a patient with severe autoimmune hemolytic anemia and human immunodeficiency virus infection. Transfusion. 1994; 34(3):248–52. PMID: 8146899

14. Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004; 39 Suppl 5:S267–75.

15. Benjamin M, Terrell DR, Vesely SK, Voskuhl GW, Dezube BJ, Kremer Hovinga JA, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009; 48(8):1129–37. https://doi.org/10.1086/597471 PMID: 19275493

16. Brecher ME, Hay SN, Park YA. Is it HIV TTP or HIV-associated thrombotic microangiopathy? J Clin Apher. 2008; 23(6):186–90. https://doi.org/10.1002/jca.20176 PMID: 18973113

17. Zimba S, Ntanda PM, Lakhi S, Atadzhanov M. HIV infection, hypercoagulability and ischaemic stroke in adults at the University Teaching Hospital in Zambia: a case control study. BMC Infect Dis. 2017; 17(1):354. https://doi.org/10.1186/s12879-017-2455-0 PMID: 28521833

18. Huson MA, Kalikman R, Hoogendijk AJ, Alabi AS, van ’t Veer C, Grobusch MP, et al. Impact of HIV infection on the haemostatic response during sepsis and malaria. Br J Haematol. 2016; 173(6):918–26. https://doi.org/10.1111/bjh.14006 PMID: 26970408

19. Dirajlal-Fargo S, Sattar A, Kulkarni M, Bowman E, Funderburg N, McComsey GA. HIV-positive youth who are perinatally infected have impaired endothelial function. AIDS. 2017; 31(14):1917–24. https://doi.org/10.1097/QAD.0000000000001556 PMID: 28590332

20. Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res. 2014; 133 Suppl 1:S21–4.

21. Arildsen H, Sorensen KE, Ingerslev JM, Ostergaard LJ, Laursen AL. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med. 2013; 14(1):1–9. https://doi.org/10.1111/j.1468-1293.2012.01027.x PMID: 22639788

22. Vaughan JL, Wiggill TM, Alli N, Hodkinson K. The prevalence of HIV seropositivity and associated cytopenias in full blood counts processed at an academic laboratory in Soweto, South Africa. S Afr Med J. 2017; 107(3):264–9. https://doi.org/10.7196/SAMJ.2017.v107i3.11206 PMID: 28281434

23. Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, et al. Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. J Infect Dis. 2017.

24. Singer M. The new sepsis consensus definitions (Sepsis-3): the good, the not-so-bad, and the actually-pretty. Intensive Care Med. 2016; 42(12):2027–9. https://doi.org/10.1007/s00134-016-4600-4 PMID: 27815587